Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS.

Multiple sclerosis and related disorders·2026
Same author

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026
Same author

Best practice recommendations for laboratory analysis and reporting of cerebrospinal fluid oligoclonal banding and associated tests for multiple sclerosis (MS): a consensus report from the harmonized CSF analysis for MS investigation (hCAMI) subcommittee of the Canadian society of clinical chemists (CSCC).

Clinical biochemistry·2026
Same author

Demographic and Clinical Characteristics of Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder in Canadian Adults.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same author

The Escalating Threat of Heatwaves in Central Asia: Climate Change Impacts and Public Health Risks.

Global challenges (Hoboken, NJ)·2025

Related Experiment Video

Updated: Apr 16, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

59.0K

Evaluating response to disease-modifying therapy in relapsing multiple sclerosis.

Mark S Freedman1, Mohammad Abdoli

  • 1The Ottawa Hospital Research Institute, University of Ottawa - Neurology, 501 Smyth Road, Ottawa, Ontario, K1H8L6, Canada.

Expert Review of Neurotherapeutics
|March 14, 2015
PubMed
Summary
This summary is machine-generated.

Identifying suboptimal responses in multiple sclerosis patients requires a comprehensive approach. Combining multiple outcome measures is crucial for predicting disease course and optimizing disease-modifying therapies.

Keywords:
disease progressiondisease-modifying therapymultiple sclerosisoptimizationsurrogate markers

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.9K

Related Experiment Videos

Last Updated: Apr 16, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

59.0K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.9K

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple sclerosis (MS) treatments show varied patient responses.
  • A need exists to identify patients with suboptimal treatment outcomes.
  • Early identification allows for timely switching of disease-modifying therapies (DMTs).

Purpose of the Study:

  • To propose a scheme for flagging patients with suboptimal responses to MS DMTs.
  • To highlight the importance of utilizing multiple surrogate markers for treatment efficacy.
  • To guide the optimization of DMT selection in multiple sclerosis.

Main Methods:

  • Review of existing treatment outcome measures in multiple sclerosis.
  • Analysis of surrogate markers for predicting disease progression.
  • Synthesis of multiple outcome data to assess treatment response.

Main Results:

  • No single validated marker accurately predicts long-term treatment efficacy.
  • A combination of various outcome measures provides a more comprehensive assessment.
  • Integrating multiple data points is essential for a holistic view of treatment response.

Conclusions:

  • A multifaceted approach using combined outcome measures is necessary for optimal MS management.
  • This strategy aids in identifying patients who may benefit from alternative DMTs.
  • Predicting the future disease course requires a comprehensive evaluation of all available surrogate markers.